作者:Clinton M. Yeung、Larry L. Klein、Charles A. Flentge、John T. Randolph、Chen Zhao、MingHua Sun、Tatyana Dekhtyar、Vincent S. Stoll、Dale J. Kempf
DOI:10.1016/j.bmcl.2005.03.008
日期:2005.5
The need for a potent HIV protease inhibitor (PI) to combat emerging PI-resistant viruses is anticipated. Analogs formulated from the combination of structural fragments of Ritonavir, Lopinavir, and Amprenavir were synthesized. Analogs containing the oxime pharmacophore were found to have improved activities against both wild type and resistant (A17) viruses. The synthesis and structure-activity relationships
预计需要一种有效的HIV蛋白酶抑制剂(PI)来对抗新兴的抗PI病毒。合成了由利托那韦,洛匹那韦和安普那韦的结构片段组合而成的类似物。发现含有肟药效基团的类似物具有针对野生型和抗性(A17)病毒的改进的活性。报道了基于该系列化合物的体外IC 50的合成和构效关系(SAR)。